CorEvitas

What CorEvitas does

CorEvitas operates as a branded real-world evidence (RWE) business unit within PPD, which is itself part of Thermo Fisher Scientific (NYSE: TMO). The company builds and operates proprietary longitudinal clinical registries that capture clinician- and patient-reported data from routine clinical practice across six therapeutic areas: dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology. The portfolio is anchored by more than 20 years of continuous data collection, approximately 500 investigator sites globally, and a patient cohort of roughly 100,000, with newly launched registries in systemic lupus erythematosus (February 2025) and Alzheimer's disease (December 2025) extending the footprint. Acquired subsidiaries Vestrum Health (retina EHR analytics, 2021) and Pregistry (pregnancy safety studies, 2022), along with PPD CorEvitas Precision Medicine as a sub-brand, round out the product surface.

The underlying platform is a multi-disease registry network in which investigator sites contribute structured longitudinal data that can be aggregated, analyzed, and licensed to biopharmaceutical customers. CorEvitas generates revenue through subscription-based access to registry data, custom observational-study and RWE services (including pregnancy and lactation studies, health economics, and patient-centered research), and ongoing registry network participation fees. Pricing is enterprise and quote-based with annual billing cadence, and the go-to-market is direct enterprise sales conducted through PPD's global commercial organization, targeting pharmaceutical and biotech companies that need regulatory-grade evidence for drug development, post-authorization safety studies, and label-expansion submissions. The primary customer segment is pharma and biotech, with secondary segments in healthcare providers and government/public health agencies.

CorEvitas was originally established in 2000, was supported by an Audax Private Equity financing round in December 2019, and is now a wholly-owned subsidiary within Thermo Fisher Scientific following PPD's 2016 acquisition by Thermo Fisher. The company's geographic footprint is global, with active operations across North America, Europe (UK), and Asia-Pacific (China and Japan), and the recently launched international Alzheimer's registry indicates continued expansion beyond its historically US-anchored base.

Name

CorEvitas

Legal name

Thermo Fisher Scientific Inc.

Website

https://corevitas.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

251–500 employees

Short description

CorEvitas, a PPD/Thermo Fisher Scientific business unit, operates proprietary longitudinal clinical registries delivering regulatory-grade real-world evidence to pharmaceutical and biotech customers across six therapeutic areas, covering 500+ investigator sites and ~100,000 patients.

Ownership category

akta.pro rank

Product category

Real-World Evidence & Clinical Registry Data Services

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Real-world evidence
• Clinical registries
• Longitudinal patient data
• Post-authorization studies
• Pharmacovigilance analytics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Registry Data Access: Subscription-based access to proprietary longitudinal registry data for pharmaceutical and biotech companies conducting drug development, post-authorization safety studies, and real-world evidence generation.
2. Observational Studies and RWE Services: Custom study design and real-world evidence generation services including pregnancy and lactation studies, health economics, and patient-centered research.
3. Registry Network Participation: Engagement of investigator sites and physicians in registry networks, creating recurring data collection and study opportunities.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

CorEvitas operates a portfolio of proprietary longitudinal clinical registries that collect regulator-grade clinician- and patient-reported real-world data across dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology therapeutic areas. It sells subscription-based access to this registry data and delivers custom observational studies, post-authorization safety studies, pregnancy and lactation research, and patient-centered evidence services to pharmaceutical and biotech customers. Supporting offerings include precision medicine real-world data and retina EHR analytics via the acquired Vestrum Health platform.

Product overview

CorEvitas (operating as PPD CorEvitas under Thermo Fisher Scientific) is a multi-product platform offering proprietary longitudinal clinical registries. The core offering is the PPD CorEvitas Clinical Registries platform with over 20 years of proprietary data collection, which includes disease-specific registries across Dermatology, Gastroenterology, Neurology, Obesity, Pregnancy, and Rheumatology. The portfolio includes acquired brands such as Vestrum Health (retina EHR data analytics) and Pregistry (pregnancy safety studies). Additional offerings include PPD CorEvitas Precision Medicine for targeted therapeutic approaches. Together, these products enable regulatory-grade real-world evidence generation for pharmaceutical and biotech companies.

Differentiator

Problem solved

Functional benefit

Brands

• PPD CorEvitas Clinical Registries: Proprietary real-world data registries covering dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology therapeutic areas

Products and services

• PPD CorEvitas Clinical Registries

Quantifiable outcome

• 500+ investigator sites and 100,000 patients across registry portfolio
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Thermo Fisher ScientificcoreOthersCorEvitas operates as a subsidiary/business unit within PPD, which is part of Thermo Fisher Scientific. The integration provides access to Thermo Fisher's full-service clinical research organization capabilities, laboratory services, and global infrastructure.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• IQVIA: Largest global CRO and real-world evidence provider, offering proprietary datasets, observational studies and analytics services to biopharma. Overlaps directly with CorEvitas in registry-based RWE and longitudinal clinical data.
• Flatiron Health: Oncology-focused real-world evidence company (acquired by Roche) that aggregates EHR data from oncology practices. Comparable as a longitudinal disease-specific RWE platform serving biopharma for drug development and regulatory submissions.
• Health Catalyst: Healthcare data and analytics platform providing real-world data infrastructure and analytics to providers, payers and life sciences. Comparable in selling longitudinal clinical data assets to biopharma.
• Parexel International: Global CRO with established real-world evidence, post-marketing and observational research capabilities. Comparable business model and biopharma customer base to CorEvitas.
• ICON plc: Major global CRO with real-world evidence and late-phase research capabilities post-PRA Health Sciences acquisition. Competes directly for biophara real-world data and post-authorization study contracts.
• Syneos Health: Biopharma solutions organization offering clinical development and real-world evidence services. Directly competes for biopharma RWE and observational study engagements.

Others

• Veradigm (formerly Allscripts): EHR vendor with real-world data offerings derived from its installed provider base. Not a direct CRO competitor but a data infrastructure peer whose EHR-extracted datasets compete for the same RWE buyer budgets.

Broad incumbents

• Cognizant (TriZetto / RWE Services): Large IT services firm with healthcare data, real-world evidence and life sciences analytics offerings. Competes for biopharma RWE and clinical data engagements, particularly with payer and provider data sources.
• Optum (UnitedHealth Group): Massive healthcare data and analytics business combining claims, EHR and pharmacy data. Broad incumbent offering real-world evidence at greater scale than CorEvitas, often competing for the same biopharma RWE budget.
• Medidata Solutions (Dassault Systèmes): Clinical trial technology and data platform serving biopharma with trial data capture, analytics and real-world data capabilities. Adjacent offering set to CorEvitas registries within the same sponsor buyer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/corronadata
• YouTubeyoutube.com/PPDCRO
• Facebookfacebook.com/PPDCRO
• LinkedInlinkedin.com/company/corevitas
• Instagraminstagram.com/ppdcro

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorEvitas